Trial Profile
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects with Non-alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Jan 2022
Price :
$35
*
At a glance
- Drugs Emricasan (Primary)
- Indications Liver cirrhosis; Non-alcoholic steatohepatitis; Portal hypertension
- Focus Therapeutic Use
- Acronyms ENCORE-PH
- Sponsors Conatus Pharmaceuticals
- 20 Dec 2019 Results published in the Journal of Hepatology
- 15 Aug 2019 Status changed from active, no longer recruiting to completed.
- 24 Jun 2019 Results presented in a Conatus Pharmaceuticals Media Release.